DOI

  • Mirjam Esther van de Velde
  • John Carl Panetta
  • Abraham J Wilhelm
  • Marleen H van den Berg
  • Inge M van der Sluis
  • Cor van den Bos
  • Floor C H Abbink
  • Marry M van den Heuvel-Eibrink
  • Heidi Segers
  • Christophe Chantrain
  • Jutte van der Werff Ten Bosch
  • Leen Willems
  • William E Evans
  • Gertjan L Kaspers

Vincristine (VCR) is frequently used in pediatric oncology and can be administered intravenously through push injections or 1 h infusions. The effects of administration duration on population pharmacokinetics (PK) are unknown. We described PK differences related to administration duration and the relation between PK and VCR-induced peripheral neuropathy (VIPN). PK was assessed in 1-5 occasions (1-8 samples in 24 h per occasion). Samples were analyzed using high-performance liquid chromatography/tandem mass spectrometry. Population PK of VCR and its relationship with administration duration was determined using a non-linear mixed effect. We estimated individual post-hoc parameters: area under the concentration time curve (AUC) and maximum concentration (Cmax) in the plasma and peripheral compartment. VIPN was assessed using Common Terminology Criteria for Adverse Events (CTCAE) and the pediatric-modified total neuropathy score (ped-mTNS). Overall, 70 PK assessments in 35 children were evaluated. The population estimated that the intercompartmental clearance (IC-Cl), volume of the peripheral compartment (V2), and Cmax were significantly higher in the push group. Furthermore, higher IC-Cl was significantly correlated with VIPN development. Administration of VCR by push led to increased IC-Cl, V2, and Cmax, but were similar to AUC, compared to 1 h infusions. Administration of VCR by 1 h infusions led to similar or higher exposure of VCR without increasing VIPN.

Original languageEnglish
Article number1789
Number of pages15
JournalCancers
Volume12
Issue number7
DOIs
Publication statusPublished - 4 Jul 2020

    Research areas

  • administration duration, adolescent, cancer, chemotherapeutic, children, exposure, infusion rate, neurotoxicity, oncovin, toxicity, vincristine

ID: 52999801